Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Invested Capital (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Invested Capital for 14 consecutive years, with $61.0 million as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 151.55% to $61.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.0 million through Dec 2025, up 151.55% year-over-year, with the annual reading at $61.0 million for FY2025, 151.55% up from the prior year.
  • Invested Capital hit $61.0 million in Q4 2025 for Coherus Oncology, down from $87.8 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $386.2 million in Q2 2021 to a low of -$196.3 million in Q1 2023.
  • Historically, Invested Capital has averaged $5.3 million across 5 years, with a median of -$76.8 million in 2024.
  • Biggest five-year swings in Invested Capital: crashed 1662.84% in 2023 and later skyrocketed 259.97% in 2025.
  • Year by year, Invested Capital stood at $179.5 million in 2021, then crashed by 176.57% to -$137.4 million in 2022, then tumbled by 38.36% to -$190.1 million in 2023, then soared by 37.74% to -$118.4 million in 2024, then skyrocketed by 151.55% to $61.0 million in 2025.
  • Business Quant data shows Invested Capital for CHRS at $61.0 million in Q4 2025, $87.8 million in Q3 2025, and $119.8 million in Q2 2025.